The US Food and Drug Administration updated its Public Health Advisory today after Health Canada ordered a suspension of marketing of Adderall and Adderall XR products in the Canadian market. Marketing was halted due to concerns about reports of sudden unexplained death (SUD) in children taking Adderall and Adderall XR.

SUD has been associated with amphetamine abuse, and reported in children with underlying cardiac abnormalities taking recommended doses of medications containing amphetamines. Adderall and Adderall XR contain amphetamines. Health Canada has received reports of a number of cases of SUD reported in children on Adderall without structural cardiac abnormalities. The FDA warned that it could not conclude at this time that Adderall causes SUD, but is continuing to evaluate data on this drug. The reported cases of SUD included one case that reported above-toxic blood levels of amphetamine.